Get started

Jnj_trade

Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
JNJ - Support Confluence Can be Nice BuyHi Guys, the opinions expressed ere are of my own. This is not financial advise and i am not a financial advisor. Okay lets jump right in! This is on the WEEKLY timeframe. Since JNJ is a divi stock, this for me would be long term hold or swing. Indicators: 1. 200 Week moving average (red line) - ABbreviation= (200 "WMA") 2. RSI Historically, as you can see everytime JNJ comes down to the Red line, the 200 Week Moving Average, it has been majority of times a good place to buy. Not only that we are hitting a support line that has held since January 2021. This is confluence, of 2 major supports, adding favor in my opinion to buy here. I would wait for this weeks close on the weekly time frame to gauge at the condition of the candle. But generally, a bottom wick is a good sign and shows buying pressure. The RSI is also in oversold territory. It can be that we go further indicating some more downward pressure. BUT looking at past history, it has always been a good opportunity to buy when RSI goes below the green line i drew. Stop loss for me would be around 5% below the weekly moving average. Ofcourse price action CAN crashes below the 200 WMA like some of the situations in history for example my "eh". But thats why we protect ourselves with stop losses. Anyway, tried to keep this simple. Hope this helps. Let me know what you think! Like, Comment, Follow! Thanks Disclaimer: The ideas expressed here are my own opinion, this is by no means financial advise. I am not a financial advisor. Just a student of the charts expressing!
NYSE:JNJLong
by SafofAllTrades
5
Johnson & Johnson|Fundamental Analysis|Price action| MUST READ!In a nutshell, Johnson & Johnson's third-quarter results were generally good. The company reported a 10.7% year-over-year increase in revenue to $23.3 billion. Adjusted earnings per share rose 18.2% to $2.60, well above the consensus estimate of $2.35. Given the large earnings outperformance, you'd probably think the health care company's stock should have rallied Tuesday after the quarterly report was released. And you'd be right. J&J stock opened up about 1% and gained even more momentum during the day. Perhaps the rise would have been greater had it not been for the company's third-quarter earnings, which came in below analysts' average forecast of $23.7 billion. But there was more to this story for the health care giant than just the underlying numbers. Here are three things you might have missed about Johnson & Johnson's third-quarter results. First and foremost, three products accounted for 63% of the growth. Many investors love Johnson & Johnson largely because of its diversification. The company has three multi-billion dollar business segments targeting different areas of healthcare. Hundreds of products are sold in these segments. In 2020, J&J claimed 28 products or platforms with annual sales of more than $1 billion. Although Johnson & Johnson's business is broadly diversified, the drivers of its growth in the third quarter were not. Just three products accounted for about 63% of the company's total revenue growth. These products accounted for nearly 90% of J&J's pharmaceutical sales growth. Not surprisingly, the COVID-19 vaccine tops the list. It brought in $502 million in the third quarter, up from no revenue the previous year. The multiple myeloma drug Darzalex took a respectable second place. Sales of the drug totaled $1.58 billion in the third quarter, up 43.7% from nearly $1.1 billion in the same quarter in 2020. J&J's Stelara drug was the third-largest growth driver in the third quarter. Sales of the plaque psoriasis and psoriatic arthritis drug totaled $2.38 billion in the quarter. That's a 22.2% increase over sales of $1.95 billion in the previous quarter. Second, it's important to keep in mind that the COVID-19 pandemic continues to have a major impact beyond just the vaccine. Johnson & Johnson's COVID-19 vaccine certainly contributed significantly to the good third-quarter results. And it could make an even bigger furor in the future. J&J is likely to benefit significantly from booster sales (if, as expected, it gets approved for boosters). However, COVID-19 also continues to have a significant impact on J&J's fortunes beyond the vaccine. Johnson & Johnson's consumer health business, for example, has been helped by increased sales of the drug Tylenol. The company noted that some of the increase in sales of the over-the-counter drug was due to its use to relieve vaccine-induced symptoms. J&J also reported that sales of ORSL HCP electrolyte drinks increased due to relief of COVID-19 symptoms. It wasn't all good news, however. Sales bans in parts of the Asia-Pacific region had a negative impact on sales of baby care products. The company said growth in sales of its Imbruvica cancer drug was partially held back by COVID-19-related dynamics. In addition, sales of J&J's orthopedic medical products in the spine, sports, and other category fell mainly because of the impact of COVID-19 on the market. Finally, the company is now on the cusp of an international tipping point. Although based in the U.S., Johnson & Johnson has been a major competitor in global markets for most of its history. And now the health care giant is nearing a crucial international stage. In the third quarter, J&J's U.S. sales rose 7.9 percent year over year to just under $12 billion. Its international sales jumped 13.8% to $11.4 billion. International markets now account for 48.7% of total revenue. At the current rate of growth, by next year more than half of Johnson & Johnson's revenue will come from outside the United States. Investors should see this as a decidedly positive trend. Greater geographic diversification of revenues could make Johnson & Johnson even more stable than it is now.
NYSE:JNJShort
by FOREXN1
6
Johnson & Johnson Stock Daily AnalysisHello everyone, as we all know the market action discounts everything :) _________________________________Make sure to Like and Follow if you like the idea_________________________________ The Johnson & Johnson stock is having a great Bullish movement right now, In the last week, the stock price has risen from 173.05 and reached 179.47 today. That's more than 3.7% in 1 week. Both the short-term and long-term trends are positive. This is a very positive sign. We are looking at 2 different Scenarios for the next period of time : Scenario 1 : The price has gone up and reached the resistance zone at 178.51 to 179.17 and its currently above it but it hasn't closed above it yet, That means the market is still moving in a Bullish way but until we have our confirmation we cant say the price is gonna keep going, but all the signs are Bullish After today's candle closes we will have our confirmation and the price will most likely continue his journey up reaching the 180.45 level. Scenario 2 : The price has gone up and reached the resistance zone at 178.51 to 179.17, Here the Bears has a Chance to show some control over the market action, The bulls are testing the Bear right now, And if the Bulls were to fail then the bears will take some control and we will see the price dropping from the resistance zone and its gonna be headed near the support line at 176.57, where a Battle will happen between the Bears and the Bulls and the outcome will determine the movement of the stock for the next period of time. Technical indicators showing this : 1) The Market price is currently trending above the 5 10 20 50 100 and 200 MA and EMA (Bullish sign) 2) The MACD is above the 0 Line showing that the market is in a Bullish state, With a positive crossover between the MACD line and Signal line. 3) The ADX is at 31.68 showing that the market is currently trending, With a positive crossover between DI+ (36.78) and DI- (10.24) Support & Resistance points : support Resistance 1) 176.57 1) 178.51 2) 175.29 2) 179.17 3) 174.63 3) 180.45 Fundamental point of view : JNJ has a Return On Assets of 10.07%. This is amongst the best returns in the industry. The industry average is -32.26%. JNJ outperforms 94% of its industry peers. The Earnings Per Share has grown by a nice 14.55% over the past year. JNJ has an Altman-Z score of 4.59. This indicates that JNJ is financially healthy and has little risk of bankruptcy at the moment. Biden administration officials reportedly plan to recommend booster doses of Pfizer and Moderna’s Covid-19 vaccines to most Americans eight months after they received their second dose. This could Affect the Johnson & Johnson stock as other company's Vaccine such as Pfizer and Moderna is being used far more often and being recorded for giving better result than the JNJ Vaccine . This is my personal opinion done with technical analysis of the market price and research online from fundamental news for The Fundamental point of view, not financial advice. If you have any questions please ask and have a great day !! Thank you for reading.
NYSE:JNJLong
by GabiDahduh
2
JNJ: Bearish Breakdown Analysis 4H (Apr. 26)X FORCE GLOBAL ANALYSIS: Johnson & Johnson has shown great momentum in its small rally over the past few weeks. However, technicals demonstrate signs of prices having temporarily topped out. Technical Analysis - The first thing we spot is a textbook bearish divergence. - Prices form higher highs, while the Relative Strength Index (RSI) forms lower highs - The Moving Average Convergence Divergence (MACD) has formed a death cross, with increasing bearish histograms - We have broken down from the ascending parallel channel, and the support has now become resisance - Prices have been testing the upper resistance of the Bollinger bands, and a test of the lower support is highly likely - We have two price gaps on the 4H chart, waiting to get potentially filled - The volume is decreasing as bearish tensions increase What We Believe Although JNJ is a fundamentally sound stock, and still great for the long run, short term technicals demonstrate a potential downside. Trade Safe.
NYSE:JNJShort
by XForceGlobal
JOHNSON & JOHNSON (JNJ) Monthly, Weekly & DailyTrades made when the monthly, weekly and daily arrows are pointing in the same direction are the most profitable. For best results trade in the direction of the trend. The Linear Regression channel is used to determine trend direction. The Linear Regression is set at 2 -2 30. When a green Henikin Ashi candle intersects with the linear regression upper deviation line (green line) and both indicators intersect with a Djinn prediction date a sell is triggered. When a red Henikin Ashi candle intersects with the linear regression lower deviation line (red line) and both indicators intersect with a Djinn prediction date a buy is triggered. This trading strategy works on daily, weekly and Monthly Djinn Predictive charts. This is not trading advice. Trade at your own risk.
NYSE:JNJ
by Dinjin